Kuros Biosciences signed sales and distribution agreements for MagnetOs bone graft, covering the Austria, Finland, the Netherlands and Switzerland.
Lubbers Medical has non-exclusive rights to sell MagnetOs in the Netherlands. Kuros signed exclusive stocking distributor agreements for Switzerland and Austria with Orthocontor and Amacord, respectively, and Kuros and Arthrone signed a letter of intent and expect to sign a full stocking distributor agreement for Finland by the end of 2Q21.
These new territories are in addition to the existing agreement with Axis Spine Limited in the U.K., which has been marketing MagnetOs since 2017.
Joost de Bruijn, Chief Executive Officer of Kuros, said, “We are pleased to finalize these sales and distribution agreements, which recognize the unique osteoinductive properties of MagnetOs, with respected partners across Northern Europe following a competitive process. Sales of MagnetOs are accelerating, and these agreements will enable further expansion.”
Kuros Biosciences signed sales and distribution agreements for MagnetOs bone graft, covering the Austria, Finland, the Netherlands and Switzerland.
Lubbers Medical has non-exclusive rights to sell MagnetOs in the Netherlands. Kuros signed exclusive stocking distributor agreements for Switzerland and Austria with Orthocontor and Amacord,...
Kuros Biosciences signed sales and distribution agreements for MagnetOs bone graft, covering the Austria, Finland, the Netherlands and Switzerland.
Lubbers Medical has non-exclusive rights to sell MagnetOs in the Netherlands. Kuros signed exclusive stocking distributor agreements for Switzerland and Austria with Orthocontor and Amacord, respectively, and Kuros and Arthrone signed a letter of intent and expect to sign a full stocking distributor agreement for Finland by the end of 2Q21.
These new territories are in addition to the existing agreement with Axis Spine Limited in the U.K., which has been marketing MagnetOs since 2017.
Joost de Bruijn, Chief Executive Officer of Kuros, said, “We are pleased to finalize these sales and distribution agreements, which recognize the unique osteoinductive properties of MagnetOs, with respected partners across Northern Europe following a competitive process. Sales of MagnetOs are accelerating, and these agreements will enable further expansion.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
